Olivier Bohuon elected to LEO Pharma’s Board of Directors
LEO Pharma expands its Board of Directors with Olivier Bohuon who will join as vice chairman. With extensive experience in global pharmaceuticals and medical technology, Bohuon will contribute significantly to realising LEO Pharma’s strategy of being a global leader in medical dermatology.
Ballerup, Denmark, August 28, 2018 – On August 27 an extraordinary general meeting elected Olivier Bohuon as a new member of LEO Pharma’s Board of Directors. He will serve as the Board of Directors’ new vice chairman.
“I am excited to welcome Olivier Bohuon to LEO Pharma’s Board of Directors,” said Jukka Pertola, Chairman of LEO Pharma’s Board of Directors. “Olivier brings extensive strategic and commercial expertise in the global pharma industry. This will benefit LEO Pharma greatly as we are expanding into new innovative treatments in our ambition of being a global leader in medical dermatology,” Pertola continued.
“LEO Pharma is a company with a very strong vision. Its focus area of medical dermatology is strongly growing, highly competitive and benefiting from scientific advances in biotechnology. I am delighted to be able to help LEO Pharma succeed with its ambitious strategy,” said Olivier Bohuon.
Olivier Bohuon brings extensive experience in the global pharmaceutical and med-tech industry. He is board member of Smiths Group plc, senior independent director at Shire plc, supervisory board member at Virbac SA, and member of the National Pharmacy Academy and the Academy of Technologies. From 2011 to May 2018 Bohuon served as CEO of medical equipment specialist Smith & Nephew plc. Before that, he held positions as CEO at Laboratories Pierre Fabre, EVP, pharmaceutical products at Abbott Laboratories and SVP, director of European Commercial Operations at GlaxoSmithKline.
- ENDS -
+45 3140 6180
Information om LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 130 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,200 people worldwide. For more information, visit www.leo-pharma.com
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma and Zymeworks Enter into Bispecific Antibody Licensing and Research Collaboration23.10.2018 13:16 | pressemeddelelse
The companies will collaborate on the discovery of novel monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways with applications in dermatology, inflammation, and autoimmunity by leveraging Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms.
World Psoriasis Day 2018: Psoriasis skal tages alvorligt22.10.2018 14:10 | pressemeddelelse
Global kampagne fra LEO Pharma sætter fokus på psoriasis og hvordan sygdommen påvirker de 125 millioner mennesker, der er ramt af den(1)
LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics17.9.2018 22:34 | pressemeddelelse
LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. This alliance expands the existing partnership of the two companies signed in November 2016 to jointly discover and develop antibody-based therapies in dermatology.
LEO Pharma closes acquisition of Bayer’s prescription dermatology business in the United States4.9.2018 14:09 | pressemeddelelse
LEO Pharma and Bayer announced today the completion of the relevant closing conditions to allow the transfer of Bayer’s prescription dermatology business to LEO Pharma in the United States.
LEO Pharma A/S indlicenserer lovende ny lægemiddelkandidat fra JW Pharmaceutical til oral behandling af atopiske dermatitis24.8.2018 10:23 | pressemeddelelse
LEO Pharma får eksklusivrettigheder til at udvikle og kommercialisere JW1601 på det globale marked ekskl. Korea. JW1601 er en ny lægemiddelkandidat beregnet til oral behandling af atopisk dermatitis. JW Pharmaceutical modtager op til 402 mio. USD på forhånd og i milepælsbetalinger. Udover milepælsbetalinger vil der blive tildelt royalty.
LEO Pharma opkøber Bayers portefølje af receptpligtige lægemidler til behandling af hudsygdomme31.7.2018 15:07 | pressemeddelelse
Med et markant opkøb styrker LEO Pharma sin position på det globale marked inden for dermatologi og tager et stort skridt mod at realisere virksomhedens mål om årligt at hjælpe 125 millioner patienter i 2025.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum